', 'auto', 'clientTracker'); ga('clientTracker.send', 'pageview');
Preview Mode Links will not work in preview mode

This podcast's purpose is to bring together the field of neuroprosthetics/brain machine interfaces/brain implants in an understandable conversation about the current topics and breakthroughs.

We hope to replace needing to read scientific papers on new research in an easy to digest way.

People can share thoughts or ideas to facilitate 'idea sex' to make the field of brain implants a smaller and more personal space.

Aug 24, 2020

Brian Pepin is the CEO and founder of Rune Labs. Since 2018, Rune Labs has managed neuromodulation systems in a way that acquires the most value out of the data available through therapies. Through this process, they hope to improve current models and push the neuromodulation field forward. In this episode, Brian Pepin discusses how Rune Labs is working to improve the ways data is collected and evaluated. 

 

Top three takeaways: 

  1. The two main projects consist of precision medicine, such as decision support, and remote monitoring.
  2. The goal is to build better neuromodulation therapies in terms of collecting continuous data rather than just at a clinical visit. 
  3. The pandemic has caused a push towards remote data collection for clinical trials. 

 

 

[0:00] Ladan introduces the episode and the guest, Brian Pepin.  

 

[1:00] Brian Pepin explains the role that Rune Labs plays in neuromodulation technology. 

 

[4:00] A new Apple Watch integration allows for the collection of many types of data that can be assessed by researchers using algorithms to yield clinical results. 

 

[7:10] Patient privacy towards data collected is highly protected and regulated. 

 

[10:50] The goal of Rune Labs is to properly gather effective data that can be used to build and improve models that push the field forward. 

 

[12:30] Amid the pandemic, there has been an urgency for continuous remote monitoring in order for clinical trials to proceed.  

 

[15:30] While some patients prefer the convenience of telemedicine, others strongly prefer face-to-face interaction with clinicians.  

 

[18:15] The future goal is to have a large-scale simulation of neurological diseases in which different data and therapies could be derived from.